Archives of Clinical Pathology

Short Communication

A SCITECHNOL JOURNAL

Leukemia and Hematologic Oncology 2018 - Immunohistochemical surrogate for molecular subtype of breast carcinoma and its correlation with cyclin D1 expression

Gireesha Rawal

Vardhman Mahavir Medical College and Safdarjung Hospital, India

Background: Various prognostic parameters have been described and validated for breast cancer, but the search for newer prognostic factors continues since existing parameters do not provide sufficient information for accurate risk assessment and tailor-made treatment planning. Thus, in the St. Gallen International Expert Consensus on primary therapy of early breast cancer, 2011, breast carcinoma was classified on molecular basis. Further this correlated well with immunohistochemical expression of the tumours and was called surrogate molecular classification. Studies on Cyclin D1 have shown inconsistent and conflicting results with regards to its role in prognosis. This study was aimed at classifying breast carcinoma using surrogate molecular classification into immunophenotypes, studying the immunohistochemical expression of Cyclin D1, and correlating Cyclin D1 as well as immunophenotypes with various parameters. Fifty cases of breast carcinoma were studied and their pTNM staging and Bloom Richardson (BR) grading done. Immunohistochemistry for Cyclin D1, ER, PR, Her2neu and Ki-67 was performed, and they were classified into immunophenotypes. Majority of the cases (40%) were Luminal A subtype, and least (16%) were triple negative. Cyclin D1 positivity was seen in 54% cases. Cyclin D1 showed statistically significant decreasing positivity with increasing grade as well as with increasing stage. On correlating immunophenotype with Cyclin D1, 75% Luminal A, 75% Luminal B, 20% Her2neu enriched, and 12.5% triple negative cases were positive for Cyclin D1. This decreasing trend was statistically significant. This is one of the initial studies from India analyzing immunophenotypes and correlating them with Cyclin D1 expression, in addition to other parameters. The significant association of Cyclin D1 with low stage, low grade and Luminal immunophenotypes may indicate that Cyclin D1 is a good predictive and prognostic factor that closely interacts with hormone signaling pathway. This may aid in investigating the response and clinical outcomes of treatment targeting Cyclin D1.

Keywords

Breast carcinoma, Immunohistochemical, Cyclin D1

Background

Prominent chest sicknesses (IBCs) are heterogeneous, showing specific nuclear and pathologic features and biologic behavior. Morphologically, there are 21 unquestionable subtypes of IBC as described by the World Health Organization classification. Currently, morphologic plan, histologic assessment, status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal improvement factor receptor-2 (HER2), close by tumor stage, are used to coordinate clinical organization. The routine immunohistochemical (IHC) assessment for ER, PR, and HER2 gives fundamental prognostic and farsighted information for IBC. About 70% of IBCs are ER positive and are equipped for antiestrogen therapy. PR is by and large oversaw by estrogen, and PR criticism is connected with decreased response to tamoxifen therapy.About 12% to 20% of IBCs show HER2 quality upgrade or possibly protein overexpression, and are connected with defenseless supposition and insightful of response to antagonistic to HER2 zeroed in on treatment. Roughly 10% to 15% of IBCs are ER, PR, and HER2 negative (triple-negative chest infection [TNBC]), and these tumors at present don't have any centered around treatment.

Obtrusive bosom malignancy (IBC) is one of the main sources of mortality in ladies overall. Numerous insightful endeavors have zeroed in on a superior comprehension of IBC's oncogenic pathways and the quest for new bosom malignancy biomarkers, of prognostic and helpful prescient worth. The declaration of estrogen receptor (ER), progesterone receptor (PR) and HER2, and the recognizable proof of atomic subtypes (Luminal A, Luminal B, HER2 improved and Basal like) have significant prognostic and prescient functions in the clinical administration of IBC. Nonetheless, there are numerous different biomarkers that are identified with the movement and restorative reaction of IBC, however an absence of predictable outcomes in various examinations has restricted their utilization in clinical practice.

Chest danger (BC) is the most notable threat and driving purpose behind death in ladies. It is a heterogeneous sickness including a couple of psychotic and nuclear subtypes depicted by different outcomes and responses to a given therapy. In India, practically 100,000 women are resolved to have BC reliably and a climb to 131,000 cases is foreseen by 2020. The progressing extended data in sub-nuclear instruments of this sickness and following zeroed in on medications have attempted to improve its result.

Cyclin D1, a key cell cycle managerial protein, is encoded by the quality, CCND1 or PRAD1, arranged on chromosome 11q13. It is imperative for the ordinary lobulo-alveolar improvement of the bosom. Transgenic mice investigates various roads with respect to zeroed in on dropping of the quality encoding cyclin D1 incited poor mammary organ headway and conceded protection from progression of BC. Then again, transgenic mice intended to overexpress CCND1 in the mammary organs demonstrated abnormal mammary development and, in specific events, made BC. Cyclin D1 overexpression has been represented in up to half of human BC. Numerous scientists have demonstrated that cyclin D1 overexpression in BC is identified with a troublesome result,

Note: This work is partly presented at 14th International Conference on Leukemia and Hematologic Oncology (June 20-21, 2018| Paris, France)

yet others have yielded various outcomes. Subsequently, it is clear that reviews on cyclin D1 have indicated conflicting a lot results concerning its function in pathogenesis and furthermore prognosis. There are not many investigations from India that archive cyclin D1 articulation in BC and their relationship with other settled prognostic components.

The cyclin D1 and cyclin-subordinate kinase 4 and 6 (CDK4/6) complex pathway is associated with cell cycle guideline and a few downstream signals. During cell cycle movement, the cyclin D1-CDK4/6 complex intervenes the phosphorylation and inactivation of the retinoblastoma protein (pRb), permitting cells to advance from G1 stage to S stage. Dysregulation of the CDK4/6-cyclin D1 complex is a significant advance in the beginning of bosom malignant growth, and a few hereditary changes in cell cycle administrative proteins have been portrayed. Cyclin D1 likewise has CDK-autonomous capacities and may enact ER-interceded record freely of estrogen and subsequently possibly change the estrogen reaction. p16INK4a (p16) goes about as a CDK inhibitor by inactivating CDK4/6 and forestalling the phosphorylation of Rb. Inactivation of p16 causes unregulated steady Rb phosphorylation, bringing about loss of control of cell cycle capture. Besides, cyclin D1 may act through CDK-free pathways. Cyclin D1 collaborates with an assortment of other record factors, including estrogen receptor (ER), androgen receptor, histone deacetylases and acetylases, recommending that cyclin D1 assumes a significant part in the guideline of record, notwithstanding its CDK-subordinate capacity in cell cycle movement.

Note: This work is partly presented at 14th International Conference on Leukemia and Hematologic Oncology (June 20-21, 2018| Paris, France)